Published: 2020-08-25

A comparative study to assess the efficacy of fluticasone and mometasone in allergic rhinitis

Waqar Ul Hamid, Deepshikha Sumbria, Ihsan Ali, Rauf Ahmad


Background: Allergic rhinitis is the most prevalent of allergic diseases in the world. Pharmacotherapy remains the mainstay of treatment.  Nasal corticosteroids being the most applicable drugs for its treatment. The objective of this study was to compare the efficacy of fluticasone propionate (FP) and mometasone furoate (MF) nasal sprays in the treatment of allergic rhinitis based on total nasal symptom score (TNSS) questionnaire.

Methods: A prospective, randomized, open-label, parallel-group, comparative study was conducted among 80 allergic rhinitis patients fulfilling the inclusion and exclusion criteria. They were randomly assigned to two groups: FP and MF groups. FP group received 200 µg dose of FP nasal spray (1 spray/nostril) daily and the MF group received 100 µg dose of MF nasal spray (1 spray/nostril) daily for 8 weeks. The effects of the two agents were compared based on TNSS questionnaire in 0, 4 and 8 weeks after the beginning of the treatment.  

Results: At the end of eight weeks of treatment, both groups showed statistically significant (p<0.005) improvements from their baseline TNSS. Mean TNSS was reduced from to 9.46 to 2.716 in FP group and from 10.18 to 2.504 in MF group.

Conclusions: Both the groups showed a significant therapeutic benefit in patients with allergic rhinitis. Even though, the difference between the two is not significant for 8 weeks therapy.   


Fluticasone propionate, Mometasone furoate, Allergic rhinitis, Total nasal symptom score questionnaire

Full Text:



Bousquet J, Cauwenberge VP, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5):147-334.

Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allerg. 2007;62:1057-63.

Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2001;108(1):45-53.

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2) LEN and Aller Gen). Allergy. 2008;63(86):8-160.

Bousquet J, Cauwenberge VP, Khaled AN. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy. 2006;61:1086-96.

Mirmoezzi MS, Yazdi MS, Gholami O. Comparative study on the efficacy of mometasone and fluticasone nasal sprays for treatment of allergic rhinitis. Int J Pharmacy Pharmaceutical Sci. 2017;9(3):211-4.

Downie SR, Andersson M, Rimmer J. Symptoms of persistent allergic rhinitis during a full calendar year in house dust mite-sensitive subjects. Allergy. 2004;59(4):406-14.

Ellis AK, Soliman M, Steacy L. The Allergic Rhinitis - Clinical Investigator Collaborative (AR-CIC): nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapies. Allergy Asthma Clin Immunol. 2015;11(1):16.

Hoyte FCL, Nelson HS. Recent advances in allergic rhinitis. F1000 Faculty Rev Res. 2018;7:1333.

Lalitha A, Mamatha KR, Puttamadaiah GM. Azelastine hydrochloride nasal spray and its combination with fluticasone propionate in the management of allergic rhinitis: a comparative study. Nat J Physiol Pharm Pharmacol. 2019;9(5):356-60.

Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 study group. Ann Allergy Asthma Immunol. 1997;79:237-45.

Ratner PH, Meltzer EO, Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2009;73:651-7.

Nathan RA, Berger W, Yang W, Cheema A, Silvey M, Wu W, et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100:497-505.

Fokkens WJ, Jogi R, Reinartz S, Sidorenko I, Sitkauskiene B, Oene VC, et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy. 2007;62:1078-84.

Scadding GK, Lund VJ, Jacques LA, Richards DH. A placebo controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clin Exp Allergy. 1995;25:737-43.

Ford LB, Matz J, Hankinson T, Prillaman B, Georges G. A comparison of fluticasone propionate nasal spray and cetirizine in ragweed fall seasonal allergic rhinitis. Allergy Asthma Proc. 2015;36:313-9.

Okubo K, Okamasa A, Honma G, Komatsubara M. Efficacy and safety of fluticasone furoate nasal spray in Japanese children with perennial allergic rhinitis: a multicentre, randomized, double-blind, placebo-controlled trial. Allergy Asthma Proc. 2014;63:543-51.

Yonezaki M, Akiyama K, Karaki M, Goto R, Inamoto R, Samukawa Y, et al. Preference evaluation and perceived sensory comparison of fluticasone furoate and mometasone furoate intranasal sprays in allergic rhinitis. Auris Nasus Larynx. 2016;43:292-7.

Chandra S, Huliraj N, Gowda G, Parasuramalu GB. Randomized, open label, active-controlled study to assess and compare health-related quality of life with mometasone and formoterol versus fluticasone and formoterol dry powder inhaler in mild to moderate persistent Asthma. Asian J Pharm Clin Res. 2015;8:296-8.